School of Public Health, Qingdao University, Qingdao 266071, China.
Institute of Nutrition & Health, Qingdao University, Qingdao 266021, China.
Nutrients. 2023 Jun 19;15(12):2806. doi: 10.3390/nu15122806.
Supplemental -3 polyunsaturated fatty acids (PUFA) on bone metabolism have yielded inconsistent results. This study aimed to examine the effects of -3 PUFA supplementation on bone metabolism markers and bone mineral density through a meta-analysis of randomized controlled trials. A systematic literature search was conducted using the PubMed, Web of Science, and EBSCO databases, updated to 1 March 2023. The intervention effects were measured as standard mean differences (SMD) and mean differences (MD). Additionally, -3 PUFA with the untreated control, placebo control, or lower-dose -3 PUFA supplements were compared, respectively. Further, 19 randomized controlled trials (RCTs) (22 comparisons, n = 2546) showed that -3 PUFA supplementation significantly increased blood -3 PUFA (SMD: 2.612; 95% CI: 1.649 to 3.575). However, no significant effects were found on BMD, CTx-1, NTx-1, BAP, serum calcium, 25(OH)D, PTH, CRP, and IL-6. Subgroup analyses showed significant increases in femoral neck BMD in females (0.01, 95% CI: 0.01 to 0.02), people aged <60 years (0.01, 95% CI: 0.01 to 0.01), and those people in Eastern countries (0.02, 95% CI: 0.02 to 0.03), and for 25(OH)D in people aged ≥60 years (0.43, 95% CI: 0.11 to 0.74), treated with -3 PUFA only (0.36, 95% CI: 0.06 to 0.66), and in studies lasting ≤6 months (0.29, 95% CI: 0.11 to 0.47). NTx-1 decreased in both genders (-9.66, 95% CI: -15.60 to -3.71), and serum calcium reduction was found in studies lasting >6 months (-0.19, 95% CI: -0.37 to -0.01). The present study demonstrated that -3 PUFA supplementation might not have a significant effect on bone mineral density or bone metabolism markers, but have some potential benefits for younger postmenopausal subjects in the short term. Therefore, additional high-quality, long-term randomized controlled trials (RCTs) are warranted to fully elucidate the potential benefits of -3 PUFA supplementation, as well as the combined supplementation of -3 PUFA, on bone health.
补充 -3 多不饱和脂肪酸 (PUFA) 对骨代谢的影响结果不一致。本研究旨在通过对随机对照试验的荟萃分析,检查 -3 PUFA 补充对骨代谢标志物和骨密度的影响。使用 PubMed、Web of Science 和 EBSCO 数据库进行了系统的文献检索,更新至 2023 年 3 月 1 日。干预效果以标准均数差 (SMD) 和均数差 (MD) 衡量。此外,还分别比较了 -3 PUFA 与未处理对照、安慰剂对照或低剂量 -3 PUFA 补充剂。此外,19 项随机对照试验(RCT)(22 项比较,n = 2546)表明,-3 PUFA 补充可显著增加血液中的 -3 PUFA(SMD:2.612;95%CI:1.649 至 3.575)。然而,对骨密度、CTX-1、NTx-1、BAP、血清钙、25(OH)D、PTH、CRP 和 IL-6 没有发现显著影响。亚组分析显示,女性股骨颈骨密度显著增加(0.01,95%CI:0.01 至 0.02),年龄 <60 岁的人群(0.01,95%CI:0.01 至 0.01),以及来自东方国家的人群(0.02,95%CI:0.02 至 0.03),年龄≥60 岁的人群 25(OH)D 增加(0.43,95%CI:0.11 至 0.74),仅接受 -3 PUFA 治疗(0.36,95%CI:0.06 至 0.66),以及持续时间≤6 个月的研究(0.29,95%CI:0.11 至 0.47)。两性的 NTx-1 均减少(-9.66,95%CI:-15.60 至 -3.71),持续时间 >6 个月的研究中血清钙减少(-0.19,95%CI:-0.37 至 -0.01)。本研究表明,-3 PUFA 补充剂可能对骨密度或骨代谢标志物没有显著影响,但对短期的年轻绝经后女性可能有一些潜在益处。因此,需要更多高质量、长期的随机对照试验(RCT)来充分阐明 -3 PUFA 补充剂以及 -3 PUFA 与其他营养素联合补充对骨骼健康的潜在益处。